CTI BioPharma Corp. (Nasdaq: CTIC) today announced its intent to raise $60 million through a fully backstopped rights offering. Under the terms of the rights offering, investors as of February 13, 2020 in CTI BioPharma's common stock and preferred stock will receive a subscription right entitling them to purchase their pro rata share of the $60 million offering amount. The rights offering will be fully backstopped by BVF Partners L.P., Stonepine Capital, L.P., OrbiMed Private Investments VI, LP and New Enterprise Associates, Inc. each of which have agreed to purchase, at a minimum, its respective as-converted pro rata share of the offering amount, plus an additional amount of securities that are not subscribed for by other purchasers in the rights offering, for a total of up to $60 million.
CTI BioPharma Corp. (Nasdaq: CTIC) today announced the presentation of data from the Company's pacritinib development program, including results from the PAC203 Phase 2 clinical trial, at the 61st American Society of Hematology (ASH) Annual Meeting being held December 7-10 in Orlando, Florida.
CTI BioPharma Corp. (Nasdaq: CTIC) today announced the closing of its previously announced rights offering (the "Rights Offering"). At the closing, CTI BioPharma sold and issued an aggregate of 15,698,995 shares of its common stock (the "Common Stock") and an aggregate of 4,429.2423 shares of its series X convertible preferred stock (the "Series X Preferred") pursuant to the exercise of subscription rights and Oversubscription Rights in the Rights Offering by existing holders of CTI Biopharma's Common Stock and series O convertible preferred stock. The Rights Offering was fully backstopped by certain existing stockholders of CTI BioPharma who agreed to purchase any shares of Common Stock and/or Series X Preferred offered in the Rights Offering that were not subscribed for (the "Oversubscription Rights"). CTI BioPharma raised aggregate gross proceeds of approximately $60.0 million in the Rights Offering.
SEATTLE, Oct. 1, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTIC) today announced that it has initiated patient enrollment in the PACIFICA pivotal Phase 3 trial of its investigational myelofibrosis treatment candidate, pacritinib. The PACIFICA trial will compare the safety and efficacy of 200 mg of pacritinib administered twice daily (BID) to Physician's Choice in 180 adult myelofibrosis patients with severe thrombocytopenia (platelet counts of less than 50,000 per microliter). "Initiation of the PACIFICA Phase 3 trial is an important step forward for the company and the pacritinib development program," said Adam R. Craig, M.D., Ph.D., President and Chief Executive Officer of CTI BioPharma.
SEATTLE , May 29, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Jefferies Global Healthcare Conference ...
The Seattle biotech, which was out of compliance with Nasdaq in December, has regained its standing due to positive data shared at a conference Dec. 9.
Anyone researching CTI BioPharma Corp. (NASDAQ:CTIC) might want to consider the historical volatility of the share...
SEATTLE , June 13, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the JMP Securities Life Sciences Conference ...
CTI BioPharma Corp. (Nasdaq: CTIC) today commenced its previously announced rights offering to raise gross proceeds of approximately $60.0 million (the "Rights Offering"). Under the terms of the Rights Offering, the holders, as of 5:00 p.m., New York time, on February 13, 2020, of CTI BioPharma's common stock (the "Common Stock") and series O convertible preferred stock (the "Series O Preferred"), are entitled to exercise their subscription rights to purchase their pro rata share (assuming full conversion of the Series O Preferred into shares of Common Stock) of the $60.0 million offering amount, as more fully described in the prospectus supplement (and accompanying prospectus), dated February 14, 2020, relating to the Rights Offering (the "Prospectus"). Each subscription right may be exercised to purchase a share of Common Stock at a subscription price equal to $1.00 per share of Common Stock or, in lieu of Common Stock, an equivalent number of shares of non-voting series X convertible preferred stock (the "Series X Preferred") at a purchase price equal to $10,000 per share of Series X Preferred. The subscription rights may be exercised at any time during the subscription period of February 14, 2020 through 5:00 p.m., New York time, on March 2, 2020.
CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the fourth quarter and full year ended December 31, 2019.
SEATTLE , Nov. 4, 2019 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the third quarter and nine months ended September 30, 2019 . "We advanced our pacritinib ...
CTI BioPharma Corp. (Nasdaq: CTIC) today announced the initiation of PRE-VENT, a Phase 3 study evaluating pacritinib in hospitalized patients with severe COVID-19. PRE-VENT, a randomized, double-blind, placebo-controlled multicenter study, will compare pacritinib plus standard of care (SOC) versus placebo plus standard of care in 358 hospitalized patients with severe COVID-19, including patients with and without cancer. The primary endpoint of the trial will assess the proportion of patients who progress to invasive mechanical ventilation and/or extracorporeal membrane oxygenation or die by Day 28. CTI expects to commence enrollment of PRE-VENT in May at sites in the United States and in Europe with data expected by the end of 2020.
SEATTLE , Nov. 6, 2019 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced four poster presentations and one oral presentation supporting the Company's pacritinib development program at ...
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]
CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Needham Healthcare Conference at 10:40 a.m. EDT. The conference will be held in a virtual meeting format.
SEATTLE , Aug. 1, 2019 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the second quarter and six months ended June 30, 2019 . "We remain focused on advancing ...
Adam Craig became the CEO of CTI BioPharma Corp. (NASDAQ:CTIC) in 2017. This analysis aims first to contrast CEO...
Biotech stocks went back and forth but managed to end the week with a gain. As usual, some stocks swung wildly in reaction to catalysts, primarily clinical readouts. Aurinia Pharmaceuticals Inc (NASDAQ: ...
SEATTLE, July 18, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTIC) ("CTI" or "the Company") today announced the outcome of a Type B, End-of-Phase-2a meeting with the U.S. Food and Drug Administration ("FDA" or "the Agency") for the continued development of its investigational myelofibrosis treatment candidate, pacritinib. Following this meeting, CTI plans to evaluate 200 mg of pacritinib administered twice daily (BID) in 180 patients with myelofibrosis and severe thrombocytopenia.
CTI BioPharma Corp. (NASDAQ:CTIC) shareholders should be happy to see the share price up 17% in the last month. But...